These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 38188690)

  • 1. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.
    Zhan Y; Lin Z; Liang J; Sun R; Li Y; Lin B; Ge F; Lin L; Lu H; Su L; Xiang T; Pan H; Huang C; Deng Y; Wang F; Xu R; Chen D; Zhang P; Tong J; Wang X; Meng Q; Zheng Z; Ou S; Guo X; Yao H; Yu T; Li W; Zhang Y; Jiang M; Fang Z; Song Y; Chen R; Luo J; Kang C; Liang S; Li H; ; Zheng J; Zhong N; Yang Z
    EClinicalMedicine; 2024 Jan; 67():102359. PubMed ID: 38188690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.
    Fan X; Dai X; Ling Y; Wu L; Tang L; Peng C; Huang C; Liu H; Lu H; Shen X; Zhang W; Wang F; Li G; Li M; Huang Y; Zhang H; Li M; Ren F; Li Y; Liu C; Zhou Z; Sun W; Yi Y; Zhou D; Gao H; Pan Q; Liu H; Zhao J; Ding Z; Ma Y; Li W; Wang Q; Wang X; Bai Y; Jiang X; Ma J; Xie B; Zhang K; Li L
    Lancet Infect Dis; 2024 Feb; 24(2):129-139. PubMed ID: 38006892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
    Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Yang Z; Li Z; Zhan Y; Lin Z; Fang Z; Xu X; Lin L; Li H; Lin Z; Kang C; Liang J; Liang S; Li Y; Li S; Yang X; Ye F; Zhong N;
    Lancet Infect Dis; 2024 May; 24(5):535-545. PubMed ID: 38330975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial.
    Lu H; Zhang G; Mao J; Chen X; Zhan Y; Lin L; Zhang T; Tang Y; Lin F; Zhu F; Lin Y; Zeng Y; Zhang K; Yuan W; Liang Z; Sun R; Huo L; Hu P; Lin Y; Zhuang X; Wei Z; Chen X; Yan W; Yan X; Mu L; Lin Z; Tu X; Tan H; Huang F; Hu Z; Li H; Li G; Fu H; Yang Z; Chen X; Wang FS; Zhong N
    EClinicalMedicine; 2024 May; 71():102582. PubMed ID: 38618202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
    Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015395. PubMed ID: 36126225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial.
    Wang B; Li HJ; Cai MM; Lin ZX; Ou XF; Wu SH; Cai RH; Wei YN; Yang F; Zhu YM; Yang ZF; Zhong NS; Lin L
    EClinicalMedicine; 2023 Sep; 63():102189. PubMed ID: 37692076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
    Reis S; Metzendorf MI; Kuehn R; Popp M; Gagyor I; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD015395. PubMed ID: 38032024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial.
    Wang F; Xiao W; Tang Y; Cao M; Shu D; Asakawa T; Xu Y; Jiang X; Zhang L; Wang W; Tang J; Huang Y; Yang Y; Yang Y; Tang R; Shen J; Lu H
    Lancet Reg Health West Pac; 2023 Sep; 38():100835. PubMed ID: 37484496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
    Hammond J; Leister-Tebbe H; Gardner A; Abreu P; Bao W; Wisemandle W; Baniecki M; Hendrick VM; Damle B; Simón-Campos A; Pypstra R; Rusnak JM;
    N Engl J Med; 2022 Apr; 386(15):1397-1408. PubMed ID: 35172054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
    Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
    Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.